Leucine, the most active branched-chain amino acid, signals muscle to build and repair. The value is strongest in liver disease and modest for everyday muscle, where whole protein works more completely. The main counterweight is metabolic: higher blood levels travel with insulin resistance and diabetes. For long-term health, the value is narrow and situation-specific against a real but unproven caution. (Full Review)

Protocol

Standard dose

5–20 g/day

2:1:1 leucine-to-isoleucine-to-valine ratio; ~2–3 g leucine per serving to trigger muscle protein synthesis

Timing

Around training

Around resistance training or with the day's lower-protein meal; kept away from bedtime

Dosing pattern

Single dose

One dose that clears the leucine threshold beats splitting into smaller sub-threshold doses

Time to effect

Muscle signal

Within ~1 hour

Muscle protein synthesis signal is acute, occurring within an hour of a dose

Soreness

Days

Any perceptible effect on soreness appears over days

Muscle mass

Weeks–months

Muscle-mass changes require weeks to months of consistent use with training

Benefits

High: Acute stimulation of muscle protein synthesis; clinical support in liver cirrhosis and hepatic encephalopathy

Medium: Reduced muscle soreness and exercise-induced damage; preservation of muscle mass in aging and sarcopenia

Low: Reduced central fatigue during endurance exercise; support during fasting or low-protein intake

Speculative: Healthspan through muscle maintenance; neurological and cognitive recovery

Contraindications

Maple syrup urine disease (absolute)

Advanced chronic kidney disease (eGFR under 30 mL/min/1.73 m²)

Pre-existing insulin resistance or type 2 diabetes

Pregnancy and breastfeeding (high supplemental doses)

Key Interactions

Levodopa (anti-Parkinson's medication)

Diabetes medications (insulin, sulfonylureas such as glipizide)

Leucine-rich or mTOR-activating supplements (whey, essential amino acid blends, leucine, HMB)

Berberine and other insulin-sensitizing supplements

Risk & Side Effects

High: Association with insulin resistance and type 2 diabetes

Medium: Blunted muscle response from an incomplete amino acid profile; reduced levodopa effectiveness

Low: Gastrointestinal discomfort; chronic mTOR activation and theoretical pro-aging signaling; elevated blood ammonia in advanced liver disease

Speculative: Amyotrophic lateral sclerosis concern; serotonin and mood effects from amino acid competition

Monitoring

Marker	Target	Why
Fasting glucose	70–90 mg/dL	Detects early shift toward insulin resistance
Fasting insulin	2–5 µIU/mL	Flags rising insulin resistance before glucose changes
HbA1c	4.8–5.4%	Reflects average blood glucose over ~3 months
Plasma BCAAs	Mid-normal, stable over time	Elevated levels track with insulin resistance
ALT / AST	<25 U/L (women), <30 U/L (men)	Tracks liver status, relevant when BCAAs are used for liver support
eGFR	>90 mL/min/1.73 m²	Confirms the kidneys can handle the added nitrogen load
Triglycerides	<80 mg/dL	Rise with insulin resistance and metabolic strain

Cadence: Baseline before starting; recheck at 3–6 months after starting regular use, then every 6–12 months, and sooner with a change in health status or a large dose increase

Qualitative Assessment

Strength and physical performance (grip strength, ease of stairs, gym progress)
Muscle recovery and soreness after exercise
Energy levels and perceived exertion during training
Appetite and overall protein intake from food
Any digestive discomfort after dosing

Branched-Chain Amino Acids for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment